Login / Signup

Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.

David M FavaraLavinia SpainLewis AuJames ClarkElla DanielsStefan DiemDharmisha ChauhanSamra TurajlicNick PowellJames M LarkinNadia Yousaf
Published in: ESMO open (2021)
Rates of grade 3 ir-D/C were higher than reported in clinical trials. The 58-day median duration of CS therapy for grade 3 ir-D/C places a significant number of patients at risk of complications. We demonstrate that microscopic colitis is an important subgroup, advocating biopsies in ir-D/C even with macroscopically normal bowel.
Keyphrases
  • clinical trial
  • risk factors
  • ulcerative colitis
  • phase iii
  • irritable bowel syndrome
  • skin cancer